RLAY VS ARVN Stock Comparison

Performance

RLAY
10/100

RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ARVN
10/100

ARVN returned -64.85% in the last 12 months. Based on SPY's performance of -13.04%, its performance is below average giving it a score of 10 of 100.

Technicals

RLAY
64/100

RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

ARVN
64/100

ARVN receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

RLAY
10/100

RLAY has missed earnings 8 times in the last 20 quarters.

ARVN
10/100

ARVN has missed earnings 14 times in the last 20 quarters.

Profit

RLAY
10/100

Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ARVN
10/100

Out of the last 20 quarters, ARVN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

RLAY
53/100

RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

ARVN
41/100

ARVN has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Analyst Price Targets

RLAY

"Analyst Price Targets" not found for RLAY

ARVN
75/100

3 analysts offer 12-month price targets for ARVN. Together, they have an average target of 73.25, the most optimistic target put ARVN at 123 within 12-months and the most pessimistic has ARVN at 24.

All score calculations are broken down here to help you make more informed investing decisions

Relay Therapeutics, Inc. Common Stock Summary

Nasdaq / RLAY

Healthcare

Biotechnology

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Arvinas, Inc Summary

Nasdaq / ARVN

Healthcare

Biotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Power up your portfolio